StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/307% above fair value
$29.68−0.21 (-0.70%)

Close on Nov 18, 2026Market cap $1.77BP/E –Yield –

Agios Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Agios Pharmaceuticals's pe ratio was 3.9× on Oct 31, 2025, against 0.8× a year earlier. Over the last 2 years it ranged from 0.8× to 5.2×, with a median of 2.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Oct 31, 20253.9×+1.0
2024Dec 31, 20242.9×+2.1
2022Apr 29, 20220.8×−0.6
2021Dec 31, 20211.5×–

More Agios Pharmaceuticals figures

See a number that looks wrong?